• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    33 Stocks Moving In Friday's Mid-Day Session

    6/17/22 12:12:44 PM ET
    $ACOR
    $ADN
    $ADXN
    $AERC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Miscellaneous
    Get the next $ACOR alert in real time by email

     

    Gainers

    • Revlon, Inc. (NYSE:REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.
    • Mereo BioPharma Group plc (NASDAQ:MREO) surged 70% to $1.3580. AstraZeneca is rumored to be eyeing take over of Mereo BioPharma Group, according to a report in The Times.
    • Sesen Bio, Inc. (NASDAQ:SESN) gained 30% to $0.7700.
    • bluebird bio, Inc. (NASDAQ:BLUE) shares jumped 25.3% to $3.83. The FDA's Advisory Committee recently unanimously backed Bluebird bio’s gene therapy for a rare blood disorder.
    • Electric Last Mile Solutions, Inc. (NASDAQ:ELMS) jumped 44% to $0.4061 after jumping 100% on Thursday.
    • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) gained 21.2% to $4.7250. Rhythm Pharmaceuticals entered into a Revenue Interest Financing Agreement with HealthCare Royalty Partners for a total investment of $100 million. The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).
    • PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) gained 21.2% to $0.6280.
    • Scholar Rock Holding Corporation (NASDAQ:SRRK) shares gained 20% to $5.83. Scholar Rock reported Phase 2 topaz trial extension data showing 'sizable and sustained motor function improvement at 24 months with apitegromab for non-ambulatory patients with types 2 and 3 spinal muscular atrophy.'
    • Seagen Inc. (NASDAQ:SGEN) shares rose 18.5% to $174.00. Merck is eyeing purchase of biotech Seagen, while other unnamed suitors are also eyeing Seagen, the Wall Street Journal said.
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) gained 16.5% to $4.0777. Comera was granted U.S. patent titled 'Excipient compounds for protein processing.'
    • SoundHound AI, Inc. (NASDAQ:SOUN) jumped 16.1% to $3.10.
    • Surrozen, Inc. (NASDAQ:SRZN) gained 15.5% to $2.5650. Surrozen recently initiated dosing in Phase 1 clinical trial of SZN-043 for severe alcoholic hepatitis.
    • Sapiens International Corporation N.V. (NASDAQ:SPNS) surged 15.1% to $24.09.
    • AeroClean Technologies, Inc. (NASDAQ:AERC) jumped 14.3% to $20.25.
    • Allakos Inc. (NASDAQ:ALLK) gained 14.2% to $2.9700.
    • Kinnate Biopharma Inc. (NASDAQ:KNTE) rose 14.1% to $9.39.
    • Sight Sciences, Inc. (NASDAQ:SGHT) jumped 12.9% to $8.46.
    • Calliditas Therapeutics AB (NASDAQ:CALT) rose 8.5% to $17.26.
    • Athersys, Inc. (NASDAQ:ATHX) rose 6.6% to $0.3411 after dropping more than 12% on Thursday.

     

     

    Losers

    • Renovare Environmental, Inc (NASDAQ:RENO) dipped 73.5% to $0.0450.
    • Addex Therapeutics Ltd (NASDAQ:ADXN) shares fell 55.3% to $1.61 after the company terminated its Phase 2b/3 study of Dipraglurant for dyskinesia associated with Parkinson's disease due to slow recruitment. The company suspended its guidance amid the termination.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) fell 51.1% to $1.4899 after the company priced a $6 million offering.
    • Sidus Space, Inc. (NASDAQ:SIDU) fell 21.7% to $5.97.
    • Advent Technologies Holdings, Inc. (NASDAQ:ADN) dipped 20% to $3.1601. Advent Technologies recently announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) fell 19.5% to $2.19. Neptune Wellness appointed Raymond Silcock as Chief Financial Officer.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 19.1% to $0.5001. Acorda Therapeutics shares jumped around 55% on Thursday after the company announced Esteve Pharmaceuticals GmbH launched INBRIJA in Germany.
    • GlucoTrack, Inc. (NASDAQ:GCTK) declined 15.3% to $2.00.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) dropped 14.4% to $0.78.
    • Alvotech Ordinary Shares (NASDAQ:ALVO) fell 13.4% to $9.78.
    • Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) declined 12.2% to $10.13.
    • Heart Test Laboratories, Inc. (NASDAQ:HSCS) dropped 12% to $2.13. Heart Test Laboratories announced pricing of its IPO of 1.5 million units at a price of $4.25 per unit.
    • Dream Finders Homes, Inc. (NASDAQ:DFH) dipped 10.3% to $10.60. B of A Securities downgraded Dream Finders Homes from Neutral to Underperform and lowered the price target from $18 to $10.5.
    • Vivakor, Inc. (NASDAQ:VIVK) fell 8.8% to $2.27. Vivakor shares jumped 40% on Thursday after the company announced it signed a definitive agreement to acquire Silver Fuels Delhi and White Claw Colorado City.

     

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ADN
    $ADXN
    $AERC

    CompanyDatePrice TargetRatingAnalyst
    Calumet Inc.
    $CLMT
    4/24/2026$36.00Buy → Neutral
    Goldman
    Surrozen Inc.
    $SRZN
    4/21/2026Buy
    TD Cowen
    Scholar Rock Holding Corporation
    $SRRK
    4/21/2026$62.00Buy
    Canaccord Genuity
    Mereo BioPharma Group plc
    $MREO
    3/23/2026Overweight → Neutral
    Analyst
    Calumet Inc.
    $CLMT
    3/5/2026$19.00 → $25.00Hold
    TD Cowen
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    Rhythm Pharmaceuticals Inc.
    $RYTM
    2/19/2026$478.00Outperform
    RBC Capital Mkts
    Scholar Rock Holding Corporation
    $SRRK
    1/9/2026$55.00Buy
    Citigroup
    More analyst ratings

    $ACOR
    $ADN
    $ADXN
    $AERC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $444,844 worth of shares (18,856 units at $23.59) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/13/26 4:19:53 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Dream Finders Homes Inc.

    DEFA14A - Dream Finders Homes, Inc. (0001825088) (Filer)

    4/24/26 4:28:36 PM ET
    $DFH
    Homebuilding
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Surrozen Inc.

    SCHEDULE 13G - Surrozen, Inc./DE (0001824893) (Subject)

    4/23/26 4:59:35 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    4/23/26 8:01:24 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sidus Space Advances its Fortis Next-Generation Command and Data Handling (C&DH) System

    Microchip collaboration enables accelerated, modular, and mission‑scalable OpenVPX architectures for space and defense applications CAPE CANAVERAL, Fla., April 23, 2026 /PRNewswire/ -- Sidus Space, Inc. (NASDAQ:SIDU) ("Sidus" or the "Company"), an innovative space and defense technology company, today announced continued advancements to its Fortis Command and Data Handling (C&DH) platform, a modular 3U OpenVPX system designed to support rapid development, configuration flexibility, and long-term scalability across next-generation space and defense missions. Supported by a strate

    4/23/26 8:31:00 AM ET
    $SIDU
    Telecommunications Equipment
    Telecommunications

    Calumet, Inc. to Release First Quarter 2026 Earnings on May 8, 2026

    INDIANAPOLIS, April 23, 2026 /PRNewswire/ -- Calumet, Inc. (NASDAQ:CLMT) (the "Company," "Calumet," "we," "our" or "us"), announced today that it plans to report results for the First Quarter 2026 on May 8, 2026. A conference call to discuss the financial and operational results is scheduled for May 8th at 9:00 AM ET. Investors, analysts and members of the media interested in listening to the live presentation are encouraged to join a webcast of the call with accompanying presentation slides; parties interested in listening to the webcast may follow the link which will be made available at http://calumetspecialty.investorroom.com/events.  For those participants wishing to dial into the call,

    4/23/26 7:00:00 AM ET
    $CLMT
    Integrated oil Companies
    Energy

    Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

    Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2 2026. NTX-253 is an investigational potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The study is designed to generate a robust early-stage clinical data package assessing safety, tolerability, a

    4/23/26 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Calumet downgraded by Goldman with a new price target

    Goldman downgraded Calumet from Buy to Neutral and set a new price target of $36.00

    4/24/26 8:02:46 AM ET
    $CLMT
    Integrated oil Companies
    Energy

    TD Cowen initiated coverage on Surrozen

    TD Cowen initiated coverage of Surrozen with a rating of Buy

    4/21/26 7:35:41 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Canaccord Genuity initiated coverage on Scholar Rock with a new price target

    Canaccord Genuity initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $62.00

    4/21/26 7:34:59 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burow Kristina exercised 89,800 shares at a strike of $9.14, increasing direct ownership by 426% to 110,871 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    4/24/26 4:05:11 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Woods Keith

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    4/20/26 6:12:15 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Vaishnaw Akshay

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    4/20/26 6:10:16 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    Financials

    Live finance-specific insights

    View All

    Calumet, Inc. to Release First Quarter 2026 Earnings on May 8, 2026

    INDIANAPOLIS, April 23, 2026 /PRNewswire/ -- Calumet, Inc. (NASDAQ:CLMT) (the "Company," "Calumet," "we," "our" or "us"), announced today that it plans to report results for the First Quarter 2026 on May 8, 2026. A conference call to discuss the financial and operational results is scheduled for May 8th at 9:00 AM ET. Investors, analysts and members of the media interested in listening to the live presentation are encouraged to join a webcast of the call with accompanying presentation slides; parties interested in listening to the webcast may follow the link which will be made available at http://calumetspecialty.investorroom.com/events.  For those participants wishing to dial into the call,

    4/23/26 7:00:00 AM ET
    $CLMT
    Integrated oil Companies
    Energy

    Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

    MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2026, after the market close on Wednesday, May 6, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at ww

    4/21/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common stock to nine newly hired employees, consisting of inducement stock options to purchase an aggregate of 38,331 shares of common stock and inducement restricted stock units, covering an aggregate of 50,973 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used

    4/17/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    Leadership Updates

    Live Leadership Updates

    View All

    Flow Sciences Appoints Michael Gesser as Chief Financial Officer

    Life Sciences Finance Veteran and Flow Sciences Board Member Steps Into CFO Role to Support Company's Next Phase of GrowthRALEIGH, N.C, April 8, 2026 /PRNewswire/ -- Flow Sciences, Inc., a global leader in advanced containment solutions for laboratory and pharmaceutical environments, today announced the appointment of Michael Gesser as its chief financial officer. Gesser, who has served as a member of the Flow Sciences board of directors since 2021, will continue serving on the board while assuming executive responsibility for all finance, accounting, tax, treasury, FP&A and investor relations functions.

    4/8/26 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rhythm Pharmaceuticals Announces Changes to Board of Directors

    -- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers. "We are thrilled to welcome Kim to our Board of Directors," said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm. "Kim brings decades of leadership experience across biotechnology, diagnostics and commercial innovation, with a proven track record

    4/3/26 9:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sapiens Selects Industry Leader as Chief Marketing Officer

    Sapiens hires accomplished B2B SaaS marketing executive Eva Skidmore as Chief Marketing Officer to accelerate AI-led growth LONDON, April 1, 2026 /PRNewswire/ -- Sapiens International Corporation N.V. (Sapiens) today announced that Eva Skidmore joins the company as the Chief Marketing Officer (CMO). She will lead the global Marketing team and be responsible for advancing the company's go-to-market (GTM) strategy and transformation. She will place AI at the core of Sapiens marketing strategy to transform how the company creates, activates, and scales demand while unifying Marketing, Sales, Product, and Partnerships into a single, intelligence-driven growth engine. This will enable Sapiens to

    4/1/26 6:30:00 AM ET
    $SPNS
    Computer Software: Prepackaged Software
    Technology

    $ACOR
    $ADN
    $ADXN
    $AERC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

    SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 9:50:26 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 9:00:58 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sidus Space Inc.

    SC 13G/A - Sidus Space Inc. (0001879726) (Subject)

    11/14/24 7:31:47 PM ET
    $SIDU
    Telecommunications Equipment
    Telecommunications